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Objectives:
1. To study the role of ALDHs in BCSCs.
2. To assess ALDHbr BCSCs as prognostic markersin breast cancer.
3. To assess ALDHbr BCSCs as therapeutic targetsin breast cancer.
Conclusions:
1. ALDHs are BCSC markers tightly related with the behaviour of BCSCs, where they play afunctional role in the RA-signalling pathways, the self-protection against oxidative stress andthe chemotherapy/radiotherapy resistance.
2. ALDH1A3br BCSCs are poor prognosis markers in breast cancer.
3. ALDHbr BCSCs are possible future therapeutic targets to overcome breast cancer.
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Results:
Introduction:
Transcriptional and post-translational regulation ofALDHs in BCSCs
The role of ALDHs in theRA signalling pathways ofBCSCs
The role of ALDHs in theself-protection againstoxidative stress of BCSCs
The role of ALDHs inchemotherapy/radiotherapy resistance of BCSCs
Treatment Target Outcome
Bhola et al.
TGF-β type I receptor kinase inhibitor (LY2157299), a neutralizing TGF-β type II receptor antibody and SMAD4 siRNA
TGFβ signalling pathway of ALDHbr BCSCs in triple-negative breast cancer cell lines and mouse xenografts
Blockage of ALDHbr BCSCs expansion and prevention of recurrence after paclitaxel treatment 
Zhao et al. ALDH1A1 acetylation (K353) mimetic mutant
ALDH1A1 of ALDHbr BCSCs in breast cancer xenograft models
Tumorigenesis and tumourgrowth inhibition
Croker et al. DEAB ALDHbrCD44+ BCSCs
Long-term sensitization of ALDHbrCD44+ BCSCs to chemotherapy and radiotherapy
Wang et al. Disulfiram ALDHs involved in the self-protection against oxidative stress in ALDHbr BCSCs
Decreased stem cell properties in tumors 
Allensworth et al. Disulfiram ALDHs involved in the self-protection against oxidative stress in ALDHbr BCSCs
Oxidative stress-mediated apoptosis induction
Sirchia et al. Decitabine, a DNMT inhibitors and Trichostatin, a HDAC inhibitor and ATRA
RA signalling pathways of breast cancers Growth inhibition both in vitro and in vivo
Nguyen et al. Entinostat, a HDAC inhibitor, ATRA and low-dose Doxorubicin 
RA signalling pathways of triple negative breast cancers
Regression of established tumour xenografts
Suman et al. Psoralidin, an inhibitor of NOTCH1 signalling Notch signalling pathway of ALDHbr BCSCs Growth arrest in both breast SCs and BCSCs
Prognostic value of ALDHbr BCSCs
Therapeutic target value of ALDHbr BCSCs
Marker Prognostic value
Cui et al. ALDHbrCD44+ BCSCs
Correlated with the Ki67+ molecular subtype of invasive breast carcinoma, which is a marker of chemotherapy resistance and, therefore, poor survival.
Marcato et al. ALDH1A3br BCSCs Correlated with poor survival in triple-negative breast cancers.
Tiezzi et al. ALDH+ BCSCs Correlated with poor prognosis in locally advanced breast cancers
Marcato et al. ALDH1A3br BCSCs Correlated with high proximal metastasis in high grade breast cancers
Woodward et al. ALDH1+ BCSCs Independent predictor of worse overall survival in ER- breast cancers
Neumeister et al. ALDH1brCD44+CD24-epithelial BCSCs
Correlated with worse outcome independently of tumour grade, tumour size, ER, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and nodal status
Khoury et al. ALDH1A1+ BCSCs
Correlated with increased risk of recurrence in post-neoadjuvant chemotherapy patients with triple-negative, HER2+ and lymph-node status breast cancers 
Charafe-Jauffret et al. ALDHbr BCSCs Independent predictor of metastasis
Zhong et al. ALDH1+ BCSCs Independent predictor of recurrence and worse disease-free survival (DFS) in invasive ductal breast cancer
Qiu et al. ALDH1A3+ BCSCs Correlated with distant metastasis and worse DFS and overall survival (OS)
Opdenaker et al. ALDH1A3+ BCSCs Correlated with tumour grade in triple-negative breast cancers
Qiu et al. ALDH1A3+CD44+ BCSCs
Correlated with advanced stage, distant metastasis, high tumour size and high nodal status breast cancers and predictor of worse DFS and OS independently of the treatment received
 ALDH1A3br BCSCs are thebest ALDH markers topredict prognosis.
 ALDH1A3br BCSCs are poorprognosis markers.
 Further research is neededto adjust their prognosticvalue.
 Further research is neededregarding the bestcombination of markers.
 Further research is neededregarding the distinctionbetween ALDHbr BCSCs andALDHbr normal breast SCs.
 Further research is neededregarding the prognosticvalue of ALDHs in CTCs,DTCs and epithelial-likeBCSCs.
 The combination ofretinoids and epigeneticmodifiers is the mostpromising therapy.
 Targeting against the Notchand the TGFβ signalling ofALDHbr BCSCs inhibits theirBCSC behaviour.
 Direct targeting againstALDHs inhibits BCSCbehaviour.
 Further research is neededon the previously describedtargets and on the targetingof other ALDH-regulatoryand functional signallingpathways.
 Further research is neededregarding the distinctionbetween ALDHbr BCSCs andALDHbr normal breast SCs.
• The CSC theory proposes that CSCs are able to establish themselves, drive tumorigenesis giving rise to all cancer cell types, induce metastasis andrecurrence, because of their self-renewal, differentiation and chemotherapy/radiotherapy resistance abilities.
• Isolation of CSCs and targeting therapies against them are needed to overcome cancer.
• ALDHs are CSC markers and ALDHbr CSCs selects for poor prognosis cancers.
• ALDHs are involved in the RA signalling, the self-protection against oxidative stress and the chemotherapy/radiotherapy resistance of CSCs
